Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HBW-012336 in KRAS G12D-mutant advanced or metastatic solid tumors
CTR20252400Phase 2Active
- Sponsor
- Hyperway Pharmaceutical
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HBW-012336 in Nonhematologic neoplasms, sponsored by Hyperway Pharmaceutical. Started Jun 2025; status: active.
02
Drugs
HBW-012336
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20252400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252400.